The announcement drove a large increase in Better's stock price, but UWM, Rocket and Pennymac all saw any gains earlier in ...
Earnings call BioNTech delivered EUR 2.9 billion in 2025 revenue, surpassing guidance despite declining COVID-19 vaccine sales, aided by BMS collaboration payments. 2026 guidance targets EUR 2.0–2.3 ...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® ...
No one has had a Synchron brain-computer interface longer than Rodney Gorham. He’s still finding new ways to use it.
Google I/O is easily one of the company's most important events of the year. While Google saves its big hardware reveals for the Made by Google Pixel event later in the year, I/O is where everything ...
PRIMETIMER on MSN
What is Five Nights at Epstein’s? Wake County Schools responds to video game controversy
WCPSS blocks “Five Nights at Epstein’s” after reports that students accessed the game on school devices ...
The gross proceeds from the offering to the Company were approximately $50 million, before deducting underwriting discounts and other offering expenses and excluding any exercise of the underwriters’ ...
Libretto, the "total wealth" advice platform for financial advisors and family offices, today announced new AI features designed to streamline planning, asset allocation, and risk management. Chief ...
REalloys Inc. (NASDAQ: ALOY) (the "Company" or "REalloys"), a U.S.-based mine-to-magnet rare earth company, today announced the closing of its previously ...
EGamers.io on MSN
Gable Guardians Debuts Website Refresh with Party System, Fresh Scrolls, and Seeker SKR Rewards
In Brief New Multiplayer Features: Gable Guardians now includes a party system and private player chats, improving team collaboration and communication. Token-Driven Features: Exclusive scroll system ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L1 1 /VEGF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results